Table 2.
COVID-19-related GBS cases reported with our cases until May 2022.
| Gender | Age (years) | Serology test of SARS-CoV-2 | GBS variant | Treatment | ||||
|---|---|---|---|---|---|---|---|---|
| Male | 23 | 2–18 | Positive | 19 | AMAN | 7 | IVIG | 23 |
| Female | 14 | Negative | 5 | AIDP | 9 | Steroid | 4 | |
| Not done | 13 | MFS | 3 | Plasma exchange | 2 | |||
| FSB | 1 | Not mentioned | 13 | |||||
| Unexcitable | 1 | |||||||
| Not mentioned | 16 | |||||||
AMAN: acute motor axonal neuropathy; AIDP: acute inflammatory demyelinating polyneuropathy; IVIG: intravenous immunoglobulins; MFS: Miller–Fisher syndrome; GBS: Guillain–Barré syndrome; FSB: pharyngeal–cervical–brachial Variant.